Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? After all, consider the alternatives. And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today boasts the aroma of cinnamon and vanilla — and get started. Meanwhile, do keep us in mind if you hear anything interesting. We love secrets. Have a smashing day.

Takeda Pharmaceuticals (TKPYY), which is Japan’s largest drug maker, is considering a bid for Shire (SHPG) to help expand in rare diseases such as hemophilia, as well as hyperactivity drugs, and to gain greater entree to the U.S. market, Reuters writes. For now, Takeda says its interest is “at a preliminary and exploratory stage” and no approach has been made to the Shire board, but the company has until April 25 to decide whether to make a bid. Shire has been under pressure due to greater competition from generic drugs and a debt pile that stems from its $32 billion acquisition of Baxalta in 2016.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy